1	L	
_	L	
-		

2	Full title: Impact of malaria diagnostic choice on monitoring of Plasmodium falciparum
3	prevalence estimates in the Democratic Republic of the Congo and relevance to control programs
4	in high-burden countries
5	
6	Short Title: Impact of assay choice on malaria prevalence estimates
7	Alpha Oumar Diallo ¹ , Kristin Banek ² , Melchior Mwandagalirwa Kashamuka ³ , Joseph Alexandre
8	Mavungu Bala ³ , Marthe Nkalani ³ , Georges Kihuma ³ , Tommy Mambulu Nseka ⁴ , Joseph Losoma
9	Atibu ³ , Georges Emo Mahilu ³ , Lauren McCormick ¹ , Samuel J. White ² , Rachel Sendor ¹ , Cyrus
10	Sinai ⁵ , Corinna Keeler ¹ , Camelia Herman ⁶ , Michael Emch ^{1,5} , Eric Sompwe ⁴ , Kyaw Lay Thwai ¹ ,
11	Rhoel R. Dinglasan ⁷ , Eric Rogier ⁶ , Jonathan J. Juliano ^{1,2} , Antoinette Kitoto Tshefu ^{3a} , Jonathan B.
12	Parr ^{2a} *
13	
14 15	¹ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
16 17	² Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
18 19	³ Ecole de Santé Publique, Faculté de Médecine, University of Kinshasa, Kinshasa, Democratic Republic of the Congo
20	⁴ Programme National de Lutte Contre Paludisme, Kinshasa, Democratic Republic of the Congo
21 22	⁵ Department of Geography, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
23 24	⁶ Malaria Branch, Division of Parasitic Diseases and Malaria, Center for Disease Control and Prevention, Atlanta, Georgia, USA
25 26	⁷ University of Florida Emerging Pathogens Institute, Department of Infectious Diseases & Immunology, College of Veterinary Medicine, Gainesville, Florida USA
27	
28	^a Co-senior authors; * Corresponding author: jonathan_parr@med.unc.edu (JBP)

30 Abstract

31	Malaria programs rely upon a variety of diagnostic assays, including rapid diagnostic
32	tests (RDTs), microscopy, polymerase chain reaction (PCR), and bead-based immunoassays
33	(BBA), to monitor malaria prevalence and support control and elimination efforts. Data
34	comparing these assays are limited, especially from high-burden countries like the Democratic
35	Republic of the Congo (DRC). Using cross-sectional and routine data, we compared diagnostic
36	performance and Plasmodium falciparum prevalence estimates across health areas of varying
37	transmission intensity to illustrate the relevance of assay performance to malaria control
38	programs. Data and samples were collected between March-June 2018 during a cross-sectional
39	household survey across three health areas with low, moderate, and high transmission intensities
40	within two health zones of Kinshasa province, DRC.
41	Samples from 1,431 participants were evaluated using RDT, microscopy, PCR, and BBA.
42	P. falciparum parasite prevalence varied between diagnostic methods across all health areas,
43	with the highest prevalence estimates observed in Bu (57.4-72.4% across assays), followed by
44	Kimpoko (32.6-53.2%), and Voix du Peuple (3.1-8.4%). Using latent class analysis to compare
45	these diagnostic methods against an "alloyed gold standard," the most sensitive diagnostic
46	method was BBA in Bu (high prevalence) and Voix du Peuple (low prevalence), while PCR
47	diagnosis was most sensitive in Kimpoko (moderate prevalence). RDTs were consistently the
48	most specific diagnostic method in all health areas. Among 9.0 million people residing in
49	Kinshasa Province in 2018, the estimated P. falciparum prevalence by microscopy, PCR, and
50	BBA were nearly double that of RDT.

Comparison of malaria RDT, microscopy, PCR, and BBA results confirmed differences
in sensitivity and specificity that varied by endemicity, with PCR and BBA performing best for

- 53 detecting any *P. falciparum* infection. Prevalence estimates varied widely depending on assay
- 54 type for parasite detection. Inherent differences in assay performance should be carefully
- 55 considered when using community survey and surveillance data to guide policy decisions.

56 Introduction

57 Malaria programs rely upon various diagnostic assays to monitor malaria prevalence and 58 to support control and elimination efforts. Though malaria rapid diagnostic tests (RDTs) and 59 microscopy historically account for nearly all point-of-care clinical *Plasmodium falciparum* 60 diagnoses and surveillance methods in endemic regions, high-throughput polymerase chain 61 reaction (PCR) assays and bead-based immunoassays (BBA) are gaining traction in large surveys 62 worldwide.

Unique features of each assay and the targets they detect are known to influence their 63 performance characteristics in different settings. For example, microscopy or PCR detection is 64 largely limited to the period of active infection, whereas RDT or immunoassay detection of P. 65 falciparum histidine-rich protein 2 (HRP2) can extend weeks after clearance of infection because 66 antigen often lingers in the blood [2]. These differences can be beneficial or serve as limitations 67 depending on the question at hand and the epidemiological setting. Prior comparisons of RDT, 68 microscopy, and PCR suggest that local malaria transmission intensity is an important 69 70 determinant of their diagnostic performance [1]. However, data comparing all four assays – 71 RDT, microscopy, PCR, and BBA is limited, especially from high-burden countries. The World Health Organization recently called for renewed efforts to address malaria in 72 73 high-burden countries. 70% of the world's malaria cases are concentrated in only 11 countries, 74 [3] 10 of which are in sub-Saharan Africa. All of these countries reported increases in malaria cases in 2020, continuing a trend that started well before the COVID-19 pandemic [4]. Efforts to 75 76 move away from "one size fits all" approaches and toward interventions tailored to the local 77 epidemiology are required to achieve sustained progress against malaria [3]. This is especially true in the Democratic Republic of the Congo (DRC), where 78 79 approximately 12% of global malaria cases and 26 million annual infections occur across a

diverse landscape of malaria transmission intensities [4]. Leveraging samples collected during the baseline survey of a longitudinal malaria transmission study in Kinshasa Province [5,6], we sought to compare malaria diagnostic performance for surveillance in sites with low, moderate, and high *P. falciparum* parasite prevalence and across all ages. We observed differences in performance by test type and modeled the impact of diagnostic assay choice on monitoring province-level prevalence estimates, emphasizing the importance of local context when choosing or interpreting results of malaria diagnostic assays.

87

88 Methods

89 Data source and study population

We performed all four malaria diagnostic assays–RDT, microscopy, PCR, and BBA–on
blood samples and data collected in March-June 2018 (rainy season) as part of a prospective,
longitudinal study of malaria conducted in urban and rural communities in Kinshasa Province.
The first phase of the cohort was conducted from 2015-2017 [5,6] followed by a second phase
conducted from 2018-2022 (the Longitudinal Epidemiological and Entomological Study of
Malaria and its Vectors in Kinshasa Province). This cross-sectional sub-study was conducted
among samples from individuals during the second phase baseline household visit.

97 Detailed methods regarding participant sampling and enrollment have been described 98 previously [5,6]. Briefly, two health zones within Kinshasa province were selected based on 99 historic malaria prevalence, ecological diversity to cover the urban/rural gradient, and 100 accessibility year-round by the research team. Bu and Kimpoko health areas, nested within 101 Maluku 1 health zone (rural), were selected to represent high and moderate malaria endemicity 102 settings, respectively (**Fig 1**). The Voix du Peuple health area, within Lingwala health zone 103 (urban), serves as a low malaria endemicity setting and is located within the Kinshasa

104 metropolitan region, the DRC's capital and one of the world's largest and fastest-growing cities

105 [7].

106

- 107 Fig 1. Location of study sites by health area. Three rural villages in Bu health area, three peri-
- 108 urban villages in Kimpoko health area, and one urban neighborhood in Voix du Peuple health
- 109 area were included, all located within Kinshasa Province.

111	All persons aged six months or older that normally lived in the household were eligible
112	for inclusion. Eligible individuals provided informed consent or minor assent (individuals aged
113	7-17 years) administered in Lingala or French before enrollment in the second phase. We
114	restricted this analysis to participants with results from all four malaria diagnostic assays – RDT,
115	microscopy, PCR, and BBA. Every participant provided informed consent for study participation
116	and for collection, storage, and use of biological specimens. In addition to parental consent, all
117	children 7-17 years old provided written assent to participate. The study was approved by the
118	Ethical Committee of the Kinshasa School of Public Health (# ESP/CE/021/2017) and the
119	University of North Carolina (UNC) Institutional Review Board (# 17-1588) and determined to
120	be an activity not involving human subject research by the Human Subjects office of the Centers
121	for Disease Control and Prevention (project 0900f3eb81bec92c).
122	
123	Data collection

124 At the baseline visit of the second phase study, trained staff administered a questionnaire

derived from the Demographic and Health Surveys (MEASURE-DHS, Rockville, MD).

126 Household heads were asked questions on household characteristics to assess household wealth

127 (i.e., housing materials, asset ownership, electrification, and water source). In addition,

respondents were asked to provide individual demographic information, bednet ownership, age,

and usage, and basic health information related to malaria, such as having a prior malaria

130 diagnosis, medications received, and presence of a fever.

131

132 Rapid diagnostic test (RDT) and microscopy diagnosis

133	Following completion of the questionnaire, a laboratory technician collected whole blood
134	by finger- or heel-prick from household participants for RDT, slide preparation, and dried blood
135	spot (DBS) collection. During the household visit, whole blood was applied to an SD Bioline
136	Malaria Ag P.f./Pan-pLDH RDT (05FK60, Alere, Gyeonggi-do, Republic of Korea), and results
137	were interpreted on-site according to the manufacturer's protocol. This RDT detects P.
138	falciparum histidine-rich protein 2 (HRP2) and pan-Plasmodium lactate dehydrogenase (pLDH)
139	antigens. If positive by either RDT band, the participants were referred to their local health
140	center and treated according to national guidelines. Next, a laboratory technician prepared a thick
141	smear slide labeled with participant codes and the date and time of collection. In brief, a small
142	drop of finger- or heel-prick blood was spread on glass slide and allowed to air dry and stained
143	with 3% Giemsa (Merck, Rahway, NJ, USA; or VWR, Radnor, PA, USA) for 30 minutes
144	Slides were transported to the study laboratory in Kinshasa, read once by expert microscopists,
145	with review by a second microscopist any time the initial microscopist observed a form of
146	parasite not clear or familiar to them. All slides were read until at least 200 white blood cells
147	(WBCs) were counted. For slides with <100 asexual parasites observed after counting 200
148	WBCs, review continued until 500 total WBCs had counted. Microscopy parasite densities were
149	estimated using the equation: (number of counted parasites x 8,000)/(number of counted WBCs).
150	

151 Sample processing and P. falciparum polymerase chain reaction (PCR)

Dried blood spot samples (DBS) were collected onto Whatman filter paper (GE Healthcare, Chicago, IL, USA), dried at ambient temperature, and stored with desiccant at -20 °C in Kinshasa until shipment to UNC for processing and PCR testing. DNA used for PCR was extracted from three 6mm punches per subject using Chelex 100 resin and Tween, as previously

described [8]. The real-time PCR assay targets the P. *falciparum*-specific lactate dehydrogenase (*pfldh*) gene with a lower limit of detection of 5–10 parasites/ μ l [9,10]. The quantitative PCR assay was performed using reaction conditions, primers, and quality control measures for highthroughput PCR as previously described, with the exception that assays were performed in singleton and amplification by 40 cycles was considered positive [5]. Primer sequences and reaction conditions are provided in **S1 Table**.

- 162
- 163 *Multiplex bead-based immunoassay*

A single 6mm DBS punch was subjected to a multiplex BBA for detecting Plasmodium 164 antigens at the US Centers for Disease Control and Prevention (CDC) as described previously 165 [17] and rehydrated in a buffer with PBS (pH 7.2), 0.3% Tween-20, 0.5% casein, 0.5% BSA, 166 167 0.5% polyvinyl alcohol, 0.8% polyvinlypyrrolidine, 0.02% sodium azide, and 3 μ g/mL of E. coli lysate (to prevent nonspecific binding). Though only HRP2 antigen positivity is utilized for 168 analysis here, the standard BBA multiplex panel was utilized for this sample set as described 169 below. Magnetic microbeads (Luminex Corp., Austin, TX, USA) were conjugated to antigen 170 capture antibodies by an antibody coupling kit (Luminex Corp.) according to manufacturer's 171 instructions. For one milliliter of microbeads (12.5×10^6 beads) antibody coupling 172 concentrations were: anti-pan-Plasmodium aldolase antibody (pAldolase, 12.5 µg, Abcam); anti-173 pan-Plasmodium lactate dehydrogenase antibody (pLDH, 12.5 µg of clone M1209063, 174 175 Fitzgerald); anti-P. vivax LDH antibody (PvLDH, 12.5 µg of clone M1709Pv2); anti-P. falciparum histidine-rich protein 2 (HRP2, 20 µg, clone MPFG-55A, ICL Inc, Portland, OR, 176 USA). Detection antibodies were also prepared in advance by biotinylating (EZ-link Micro 177 178 Sulfo-NHS-Biotinylation Kit, Thermo Fisher Scientific, Waltham, MA) according to

manufacturer's instructions. Final prepared dilution of detection antibodies was 1.0 mg/mL and
for anti-malarial antigen specific antibodies as follows: pAldolase (Abcam, Cambridge, UK),
pLDH and PvLDH (1:1 antibody mixture of clones M1709Pv1 and M86550, Fitzgerald
Industries, Acton, MA, USA), HRP2 (1:1 antibody mixture of MPFG-55A and MPFM-55A, ICL
Inc). Upon conjugation or biotinylation, reagents were stored at 4 °C until use in the

immunoassay.

BBA reagents were diluted in buffer: containing 0.1 M phosphate buffered saline (PBS) 185 pH 7.2, 0.05% Tween-20, 0.5% bovine serum albumin (BSA), and 0.02% sodium azide. For all 186 187 wash steps, assay plate was affixed to a handheld magnet (Luminex Corp), and gently tapped for 2 min to allow bead magnetization before evacuation of liquid and washing with 150 μ L PBS, 188 0.05% Tween-20. The four bead regions were combined in dilution buffer (in a reagent trough) 189 190 and pipetted onto a 96-well assay plate (BioPlex Pro, Bio-Rad, Hercules, CA, USA) at a quantity of approximately 800 beads/region. Plates were washed twice, and 50 µL of controls or samples 191 pipetted into appropriate wells. Following 90-min gentle shaking at room temperature protected 192 from light, plates were washed three times. A mixture of detection antibodies was prepared in 193 dilution buffer (pAldolase at 1:2000, all others at 1:500), and 50 µL added to each well for a 45-194 min incubation. After three washes, 50 µL of streptavidin–phycoerythrin (at 1:200, Invitrogen) 195 was added for a 30-min incubation. Plates washed three times, and 50 µL dilution buffer added to 196 each well for 30-min incubation. Plates washed once and beads resuspended in 100 mL PBS. 197 198 After brief shaking, plates were read on MAGPIX machine (R&D Systems, Minneapolis, MN, USA) with target of 50 beads per region. The median fluorescence intensity (MFI) value was 199 generated for all beads collected for each region by assay well and subtracting the assay signal 200 201 from wells with dilution buffer blank provides an MFI-background (MFI-bg) value used for

analyses. Positive and negative controls were included on each plate to ensure assay

203 performance.

204

205 *Statistical analyses*

We estimated *P. falciparum* malaria prevalence and 95% confidence intervals (CIs) 206 207 across health areas, age categories, sex, self-reported history of fever in the last seven days, and household membership size from RDT, microscopy, PCR, and BBA results based on predicted 208 values using univariate Generalized Estimating Equations (GEE) logistic regression. The GEE 209 210 yields population-average estimates while accounting for the potential influence of sharing a household with a malaria-infected person on other members' infection status [12]. To model the 211 correlation between household members, we assumed an exchangeable working correlation 212 213 structure [13].

We estimated sensitivity and specificity using the classical contingency table approach 214 and latent class analysis (LCA) to evaluate the performance of the four diagnostic methods (i.e., 215 RDT, microscopy, PCR, and BBA) to detect *P. falciparum* malaria infection. In the contingency 216 table approach, we used PCR or BBA as the reference ("gold standard") because they are highly 217 sensitive assays that detect different targets (nucleic acid and antigen) and outperform the 218 traditional microscopy gold standard in most settings. Given that there is not a clear gold 219 standard, we also used LCA to estimate sensitivity and specificity by combining results from the 220 221 four diagnostic methods via a probabilistic model to define an internal reference standard, or "alloyed gold standard" [14–17]. 222

To inform the potential impact of malaria diagnostic method choice on malaria control
 programs – for example, during decision-making about RDT or antimalarial medication

procurement – we estimated the number of individuals with *P. falciparum* malaria infection in 225 Kinshasa Province during the phase two baseline data collection period (March-June 2018) using 226 each diagnostic method: RDT, microscopy, pfldh real-time PCR, and BBA. First, we 227 stratifiedhealth areas in Kinshasa Province into three malaria prevalence categories: prevalence 228 of 15-24% (low), 25-34% (moderate), or \geq 35% (high) using PCR-based prevalence estimates 229 from the 2013-2014 Demographic and Health Survey (DHS) [18]. We modelled Kinshasa 230 Province malaria prevalence by calculating the cluster-level malaria prevalence based on all 231 samples for each DHS cluster. Then, we fit a thin plate spline model to the cluster-level 232 233 prevalence values to spatially interpolate the malaria prevalence across Kinshasa province in areas without DHS clusters [19]. Finally, we used zonal statistics to estimate the mean malaria 234 prevalence in each health area within Kinshasa province. While there are 416 health areas in 235 236 Kinshasa Province, we could only estimate the mean malaria prevalence for 402 (96.6%) health areas, where health area population estimates from the Ministry of Health were able to be linked 237 by name to corresponding health area boundaries from a publicly available geospatial dataset 238 [20]. 239

Second, each health area in Kinshasa Province was matched with the study health area 240 241 with the most similar *P. falciparum* prevalence. Third, we estimated age-specific malaria prevalence estimates by RDT, microscopy, PCR, and BBA from the study health areas. For this 242 analysis, we stratified age into two categories, <5 and ≥ 5 years old, using age data provided by 243 244 the DRC Ministry of Health. Fourth, we generated age-specific weights by multiplying the study age-specific prevalence estimates and age distribution (<5 years: 18.9%; ≥ 5 years: 81.1%) used 245 by the DRC Ministry of Health. Fifth, we multiplied the age-specific weights by the age-246 247 stratified population estimates provided by the DRC Ministry of Health for 2018 and obtained

- from the DRC District Health Information System 2 (DHIS2) to calculate the age-specific
- 249 number of individuals with malaria by diagnostic method for 402 health areas in Kinshasa
- province [21]. Finally, we summed the estimated number of cases by diagnostic method to obtain
- estimates for the entire province. See S1 Appendix for a detailed description of these methods.
- 252 We conducted analyses in R Statistical Software (v4.1.2; [22]).

254 **Results**

- 255 Study participant description
- 256 Samples from 1,431 participants with available results for four malaria diagnostic assays
- 257 RDT, microscopy, PCR, and BBA were included in our analysis. Participants were
- distributed across the study health areas as follows: 491 (34.3%) in Bu (three rural villages), 521
- (36.4%) in Kimpoko (three peri-urban villages), and 419 (29.3%) in Voix du Peuple (one urban
- neighborhood) (**Table 1**). The median age of subjects was 20.0 years old (interquartile range:
- 11.0, 39.5), most were female (55.3%), and they shared a household with 6-10 other study
- 262 participants (59.0%).

263 Table 1. Malaria prevalence by diagnostic method (RDT, microscopy, PCR, and BBA) for

264 the detection of *Plasmodium falciparum* (N=1,431).

265

	Study		<i>P. falciparum</i> prev	valence (95% CI)	
	population				
Characteristics	N (%)	RDT ^a	Microscopy ^b	PCR ^c	BBA ^d
Overall	1,431	33.7 (29.9-37.8)	43.3 (39.3-47.5)	46.1 (41.8-50.6)	48.4 (44.0-52.8)
Health area					
Bu					
Age (years)	491 (34.3)	57.4 (51.7-62.9)	59.7 (54.0-65.1)	66.2 (60.2-71.8)	72.4 (66.9-77.2)
<5	320 (22.4)	60.6 (50.3-70.0)	53.4 (43.2-63.4)	50.3 (39.9-60.6)	72.6 (62.4-80.9)
5-14	844 (59.0)	77.2 (69.9-83.1)	71.4 (63.0-78.6)	77.6 (69.5-84.0)	85.8 (78.1-91.1)
15-24	178 (12.4)	43.6 (29.9-58.3)	68.3 (54.3-79.6)	76.7 (64.2-85.7)	69.2 (54.0-81.1)
≥ 25	89 (6.2)	34.9 (27.3-43.4)	46.0 (37.9-54.4)	59.0 (50.3-67.2)	56.3 (47.7-64.4)
Kimpoko					
Age (years)	521 (36.4)	32.6 (28.2-37.4)	50.7 (45.5-55.9)	53.2 (47.8-58.5)	51.2 (45.8-56.6)
<5	61 (11.8)	16.3 (8.8-28.2)	38.5 (27.7-50.5)	29.6 (19.8-41.8)	32.3 (22.2-44.4)
5-14	190 (36.6)	52.5 (43.9-60.9)	60.6 (52.3-68.4)	66.4 (57.9-73.9)	61.4 (52.7-69.5)
15-24	98 (18.9)	38.6 (29.7-48.3)	59.7 (49.5-69.1)	68.1 (58.6-76.3)	59.4 (49.6-68.4)
≥ 25	170 (32.8)	14.0 (9.6-20.0)	39.8 (32.4-47.7)	39.2 (31.6-47.3)	42.0 (34.7-49.7)
Voix du Peuple					
Age (years)	419 (29.3)	3.1 (1.7-5.5)	7.6 (5.1-11.2)	5.6 (3.5-8.8)	8.4 (6.0-11.6)
<5	36 (8.6)	0.0 (0.0- 0.0)	16.3 (6.3-36.0)	2.1 (0.3-14.5)	0.0 (0.0- 0.0)
5-14	101 (24.1)	5.9 (2.5-13.5)	7.6 (3.4-16.1)	8.7 (4.2-17.2)	9.8 (5.3-17.5)
15-24	119 (28.4)	3.4 (1.3-8.1)	9.1 (5.1-15.7)	8.1 (4.6-14.1)	10.9 (6.7-17.3)
≥25	163 (38.9)	2.5 (1.1-5.2)	5.5 (3.2-9.3)	3.0 (1.3-6.9)	7.4 (4.2-12.9)
Sex ^f					
Male	648 (45.3)	34.7 (30.4-39.4)	44.7 (40.0-49.5)	48.4 (43.2-53.7)	48.3 (43.1-53.6)
Female	783 (54.7)	32.9 (28.6-37.4)	42.2 (37.5-47.0)	44.2 (39.6-48.9)	48.5 (43.7-53.3)
Self-reported fever in last					
seven days					
No	1,137 (83.7)	31.2 (27.3-35.4)	41.8 (37.5-46.2)	45.6 (41.0-50.2)	47.0 (42.3-51.7)
Yes	222 (16.3)	44.6 (37.3-52.1)	50.2 (42.2-58.2)	49.2 (41.4-57.0)	55.0 (47.4-62.4)
Household members					
enrolled					
1-5	320 (22.4)	35.8 (29.4-42.8)	49.5 (42.5-56.6)	51.4 (44.3-58.6)	55.0 (47.5-62.2)
6-10	844 (59.0)	35.0 (29.9-40.5)	41.8 (36.5-47.3)	46.1 (40.2-52.1)	47.1 (41.3-53.0)
11-15	178 (12.4)	25.3 (14.8-39.7)	37.5 (24.7-52.4)	33.3 (20.1-49.7)	40.1 (26.1-56.0)
16-20	89 (6.2)	9.1 (2.5-28.5)	16.8 (6.6-36.8)	15.7 (5.0-39.6)	13.5 (3.7-39.0)

Abbreviations: 95% CI, 95% confidence interval; BBA, bead-based immunoassay; PCR, polymerase chain reaction; RDT, rapid
 diagnostic test.

^a Used generalized estimating equation logistic regression to estimate prevalence and 95% CI

^b HRP2-band positive, ^b Any *Plasmodium* species visualized, ^c *P. falciparum* lactate dehydrogenase PCR-positive, ^d *P.*

270 *falciparum* HRP2 antigen positive

^f Self-reported at enrollment.

272 *P. falciparum infection prevalence*

- 273 *P. falciparum* parasite prevalence varied between diagnostic methods across all health
- areas, with the highest prevalence estimates observed in Bu (57.4-72.4% across assays), followed
- by Kimpoko (32.6-53.2%), and Voix du Peuple (3.1-8.4%), which we defined as "high,"
- 276 "moderate," and "low" prevalence areas, respectively (Table 1, Fig 2A). *P.falciparum*
- prevalence was consistently lowest by RDT (HRP2 band) and highest by BBA (HRP2 detection)
- and PCR (*pfldh* amplification). Across age categories, malaria prevalence was highest among
- school-aged children (5-14 years) and young adults (15-24 years), participants who self-reported
- experiencing a fever in the last seven days, and those who lived in households with 1-5 members
- enrolled.

Fig 2. *P. falciparum* prevalence and diagnostic assay performance.

- (A) *P. falciparum* prevalence and 95% confidence intervals across diagnostic assays by health
- area. (B) Diagnostic assay performance compared to an alloyed gold standard by health area. A
- diagnostic assay with perfect sensitivity and specificity would fall in the top left corner of panel
- 286 B.

- 288 *Abbreviations*: RDT, rapid diagnostic test HRP2-band; Microscopy, thick-smear light microscopy; PCR, real-time polymerase
- 289 chain reaction detecting the *pfldh* gene; BBA, bead-based immunoassay detecting HRP2 protein.
- ^aError bars are 95% confidence intervals.

291

292 Diagnostic performance for the detection of P. falciparum

293	Diagnostic assay performance for the detection of <i>P. falciparum</i> varied by endemicity
294	and gold standard choice (Table 2). In general, assay sensitivity decreased, and specificity
295	increased for the detection of <i>P. falciparum</i> when moving from higher to lower prevalence health
296	areas. Among the three diagnostic methods compared to PCR, BBA (sensitivity 79.5% [95% CI:
297	76.1-82.6]; specificity 80.2% [95% CI: 77.3-82.9]) had the highest sensitivity but lower
298	specificity than RDT and microscopy across all health areas with the exception of Voix du
299	Peuple (low prevalence). Compared to the BBA, PCR (sensitivity 75.8% [95% CI: 73.2-79.6];
300	specificity 83.0% [95% CI: 80.2-85.5]) had the highest sensitivity but a lower specificity than

302

301

RDT.

303 Table 2 Sensitivity and specificity of malaria diagnostic methods versus PCR, BBA, and LCA for the detection of *Plasmodium*

falciparum, stratified by health area and malaria prevalence.

		Versus F	PCR	Versus	BBA	LC	A
Health area prevalence	Diagnostic test	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
	RDT	73.2 (68.0-77.9)	74.2 (66.9-80.7)	76.0 (71.2-80.3)	92.0 (86.1-95.9)	84.7 (80.3-89.8)	86.7 (79.8-93.1)
Bu	Micro	78.1 (73.2-82.5)	75.4 (68.2-81.8)	73.4 (68.5-78.0)	75.2 (67.1-82.2)	84.4 (79.5-89.4)	78.8 (71.7-84.7)
high	PCR	N/A	N/A	79.9 (75.4-84.0)	70.1 (61.7-77.6)	91.0 (87.4-95.1)	73.5 (65.6-80.9)
	BBA	87.3 (83.2-90.8)	57.5 (49.6-65.1)	N/A	N/A	98.4 (95.9-100.0)	69.4 (62.1-76.8)
	RDT	57.7 (51.7-63.6)	95.4 (92.0-97.7)	55.0 (48.9-61.1)	90.5 (86.2-93.8)	79.2 (71.5-86.0)	97.8 (95.2-100.0)
Kimpoko	Micro	72.4 (66.8-77.6)	74.8 (68.8-80.1)	65.8 (59.8-71.4)	65.9 (59.7-71.7)	89.0 (83.2-93.9)	75.3 (70.0-79.9)
moderate	PCR	N/A	N/A	65.8 (59.8-71.4)	65.9 (59.7-71.7)	96.7 (92.9-99.5)	75.3 (69.4-80.2)
	BBA	72.8 (67.1-77.9)	72.7 (66.7-78.2)	N/A	N/A	86.6 (81.1-90.9)	71.7 (65.5-76.5)
	RDT	32.0 (14.9-53.5)	98.5 (96.7-99.4)	34.3 (19.1-52.2)	99.5 (98.1-99.9)	69.5 (38.2-99.9)	99.4 (98.7-100.0)
Voix du Peuple low	Micro	44.0 (24.4-65.1)	94.2 (91.4-96.3)	37.1 (21.5-55.1)	94.5 (91.8-96.6)	74.3 (46.8-100.0)	94.7 (91.9-97.0)
	PCR	N/A	N/A	37.1 (21.5-55.1)	96.9 (94.6-98.4)	72.8 (44.4-100.0)	96.8 (95.3-98.7)
	BBA	52.0 (31.3-72.2)	94.4 (91.7-96.5)	N/A	N/A	100.0 (91.2-100.0)	95.5 (93.2-98.0)
	RDT	64.7 (60.8-68.4)	92.5 (90.5-94.2)	65.2 (61.4-68.8)	95.2 (93.5-96.6)	77.8 (74.5-81.8)	99.0 (98.2-99.9)
A 11	Micro	74.2 (70.6-77.6)	84.4 (81.7-86.9)	68.4 (64.7-71.9)	81.8 (78.8-84.4)	80.5 (76.5-84.0)	86.1 (82.9-88.4)
All	PCR	N/A	N/A	75.8 (72.4-79.1)	83.3 (80.5-85.9)	88.8 (86.0-91.9)	87.5 (84.2-90.0)
	BBA	79.5 (76.1-82.6)	80.2 (77.3-82.9)	N/A	N/A	92.1 (89.6-94.6)	86.2 (83.2-88.9)

Abbreviations: 95% CI, 95% confidence interval; BBA, bead-based immunoassay; LCA, latent class analysis; Micro, microscopy; N/A, not applicable; PCR, polymerase chain

307 reaction; RDT, rapid diagnostic test.

2	1	n
J	т	υ

311	Using LCA to compare all four diagnostic methods against an "alloyed gold standard,"
312	the best diagnostic performance varied by health area (Figure 2B). The most sensitive diagnostic
313	method was BBA in Bu (high prevalence) and Voix du Peuple (low prevalence), while PCR was
314	the most sensitive diagnostic method in Kimpoko (moderate prevalence). RDT was consistently
315	the most specific diagnostic method in all health areas, regardless of the gold standard (PCR,
316	BBA, or LCA). We did not observe a single, best-performing assay.
317	
318	Estimated P. falciparum infection in Kinshasa Province by diagnostic method
319	P. falciparum infections were estimated to be 1,169,745 by BBA, 1,060,485 by PCR, and
320	1,089,525 by microscopy – all nearly double the 672,431 estimated cases by RDT (Table 3).
321	Though imprecise, these numbers approximate how diagnostic choice would influence
322	prevalence estimates across 402 health areas within 35 health zones in Kinshasa Province (Fig
323	3), with an assumed population of 9.0 million in 2018 based on DHIS2 data.
324	Table 3. Estimated number of individuals infected with <i>P. falciparum</i> in Kinshasa Province
325	in March-April 2018 by malaria diagnostic method, derived from Ministry of Health age
326	distribution and population estimates (8,993,453 people).
327	

Diagnostic	Number of	Lower 95%	Upper 95%
method	infections (%)	confidence	confidence
		limit	limit
RDT	672,431 (7.5)	515,265	918,597
Microscopy	1,089,525 (12.1)	885,581	1,364,353
PCR	1,060,485 (11.8)	869,752	1,326,532
BBA	1,169,745 (13.0)	1,090,512	1,246,787

Abbreviations: BBA, bead-based immunoassay; PCR, polymerase chain reaction; RDT, rapid diagnostic test.

Fig 3. Distribution of health area malaria prevalence by PCR from the 2013-2014

330 **Demographic Health Survey across health zones in Kinshasa Province.** Representative

- health areas included in the Kinshasa Province study of four diagnostic assays are indicated by
- text. The 25% and 35% prevalence thresholds utilized in this study to designate low, moderate,
- or high prevalence are indicated by vertical hashed lines.

334 Discussion

335

336 The performance of commonly used malaria diagnostic assays varied based on the epidemiological context in this cross-sectional household study comprising rural, peri-urban, and 337 338 urban sites with a range of parasite prevalence in a high-burden setting. Compared to an alloyed 339 gold standard, PCR and BBA had higher sensitivity for *P. falciparum* than RDT and microscopy. 340 However, neither assay outperformed the other in all contexts. BBA had the best sensitivity lowand high-prevalence sites, while PCR had the best sensitivity in moderate-prevalence sites. 341 Across all prevalence strata, RDT had the highest specificity but lowest sensitivity of all four 342 343 assays.

Differences in prevalence estimates were evident across study sites and age strata. 344 Among children younger than 15 years old in Bu health area's high prevalence sites, prevalence 345 estimates were notably higher by BBA than by PCR. People living in these villages had more 346 347 frequent infections than in other health areas and, as a result, were expected to be more likely to have lingering HRP2 antigenemia outside the window of acute infection. The highest proportion 348 of recently cleared P. falciparum infections (assessed by BBA-positive, pfldh PCR-negative) was 349 found in the high-prevalence villages of Bu health area. We also observed a high prevalence of 350 P. falciparum infection in 5- to 14-year-olds, consistent with past findings from the DRC [23]. 351 352 These findings support the argument that older children and adolescents should be routinely included in malaria surveillance activities. 353

National malaria control programs and their partners rely upon routine data, as well as community-based and health facility surveys, to guide purchasing and forecasting decisions. Parasite prevalence and malaria incidence are usually estimated using the results of RDTs, the primary malaria diagnostic method used for case management in the DRC and across sub-

Saharan Africa. However, high-throughput molecular and serological assays are becoming more
readily available throughout the region for surveillance [24]. Malaria programs will increasingly
have access to results from advanced laboratory approaches and need empirical data to guide

their decision-making.

To explore how diagnostic assay choice might impact real programmatic decisions, we 362 modeled health area P. falciparum PCR prevalence using results from the national 2013-14 363 Demographic and Health Survey and extrapolated results from our study sites to estimate 364 prevalence across all of Kinshasa Province. Kinshasa Province is the DRC's most populous 365 administrative region and includes rural, peri-urban, and urban zones, including the capital city 366 Kinshasa. Its diverse health zones thus provide an opportunity to examine how differences in 367 368 diagnostic assay performance across a variety of epidemiological contexts might impact malaria programs. Among nearly 9.0 million children and adults living across 402 health areas in 369 Kinshasa Province in 2018, based on DHIS2 data, the parasite prevalence estimates ranged from 370 371 672,431 (7.5%) to 1,169,745 (13.0%), depending on the diagnostic method.

In practical terms, the numbers used to guide RDT or artemisinin-combination therapy procurement choices could vary by nearly two-fold depending on whether they were derived from RDT or BBA results. While these differences may be self-evident to laboratory experts accustomed to interpreting differences between these assays, most programmatic staff are unaccustomed to interpreting these results. Our prevalence estimates are imprecise, but their wide range demonstrates the importance of considering the assay used and its performance characteristics when interpreting malaria survey results across different endemicities.

Our study has several limitations. First, our seven study sites provide valuable insights 379 into malaria epidemiology across different transmission intensities and geographical contexts, 380 but they are not representative of the whole country. The DRC is Africa's second largest country 381 by land mass and the fourth largest by population; it is bordered by nine other countries. For this 382 reason, we restricted our modeling efforts to Kinshasa Province and did not attempt to generalize 383 384 these findings to the entire country. Second, RDTs were developed for clinical diagnosis at the point-of-care, and their use for surveillance activities is off-label. This study's household survey 385 design did not allow us to evaluate assay performance during acute malaria infection. People sick 386 387 with malaria tend to have higher parasite densities that are readily detected by all four assays evaluated. Nonetheless, individual-level data comparing RDT, microscopy, real-time PCR, and 388 BBA results shed light on their relative strengths and weaknesses and can serve as useful data for 389 390 future modeling efforts. Third, our latent class analysis approach to generate an "alloyed gold standard" assumes conditional independence, but both the RDTs and BBA detect HRP2. This 391 assumption could bias LCA results in favor of both methods [14]. Fourth, survey data utilizing 392 advanced laboratory methodologies may become less important as the DRC National Malaria 393 Control Program, like other malaria programs in Africa, makes increasing use of routine data 394 available through the DHIS2. However, rapid expansion of molecular and serological laboratory 395 capacity across Africa will almost certainly translate to increased use of PCR and BBAs for 396 malaria surveillance during large-scale surveys in the future. 397

Comparison of RDT, microscopy, real-time PCR, and BBA results confirmed differences in sensitivity and specificity that varied by study site, with PCR and BBA performing best for detecting *P. falciparum* infection. Using a model of the *P. falciparum* prevalence across all of Kinshasa Province and routine data, we found that the number of infections varied nearly two-

- 402 fold depending on which assay was used for parasite detection. Malaria control programs should
- 403 carefully consider inherent differences in assay performance when using community survey and
- 404 surveillance data to guide planning and implementation strategies.

405	Acknowledgements: The authors thank Steve Meshnick for conceptualizing the parent study
406	and providing invaluable mentorship relevant to this project before his untimely death. They also
407	thank study participants and the Kinshasa School of Public Health field research team who made
408	this work possible.
409	Funding: This work was funded by NIH R01AI132547 to JJJ and RRD and R01AI129812 to
410	AT, with partial support from NIH K24AI134990 to JJJ and T32AI070114 to KB and RS, and

- 412 JBP.
- 413 **Competing interests:** JBP reports financial support from Gilead Sciences and non-financial
- 414 support from Abbott Diagnostics, both outside the scope of this work.

References

- 1. Wu L, van den Hoogen LL, Slater H, Walker PGT, Ghani AC, Drakeley CJ, et al. Comparison of diagnostics for the detection of asymptomatic Plasmodium falciparum infections to inform control and elimination strategies. Nature. 2015;528: S86–93. doi:10.1038/nature16039
- 2. Iqbal J, Siddique A, Jameel M, Hira PR. Persistent histidine-rich protein 2, parasite lactate dehydrogenase, and panmalarial antigen reactivity after clearance of Plasmodium falciparum monoinfection. J Clin Microbiol. 2004;42: 4237–4241. doi:10.1128/JCM.42.9.4237-4241.2004
- 3. WHO Team: Global Malaria Programme. High burden to high impact: a targeted malaria response. World Health Organization; 2018.
- 4. WHO Team: Global Malaria Programme. World Malaria Report 2021. Geneva: World Health Organization; 2021.
- Mwandagalirwa MK, Levitz L, Thwai KL, Parr JB, Goel V, Janko M, et al. Individual and household characteristics of persons with Plasmodium falciparum malaria in sites with varying endemicities in Kinshasa Province, Democratic Republic of the Congo. Malar J. 2017;16: 456. doi:10.1186/s12936-017-2110-7
- 6. Carrel M, Kim S, Mwandagalirwa MK, Mvuama N, Bala JA, Nkalani M, et al. Individual, household and neighborhood risk factors for malaria in the Democratic Republic of the Congo support new approaches to programmatic intervention. Health Place. 2021;70: 102581. doi:10.1016/j.healthplace.2021.102581
- 7. World City Populations 2021 [Internet]. [cited 2 Nov 2021]. Available: https://worldpopulationreview.com/world-cities
- 8. Teyssier NB, Chen A, Duarte EM, Sit R, Greenhouse B, Tessema SK. Optimization of whole-genome sequencing of Plasmodium falciparum from low-density dried blood spot samples. Malar J. 2021;20: 116. doi:10.1186/s12936-021-03630-4
- 9. Beshir KB, Hallett RL, Eziefula AC, Bailey R, Watson J, Wright SG, et al. Measuring the efficacy of antimalarial drugs in vivo: quantitative PCR measurement of parasite clearance. Malar J. 2010;9: 312. doi:10.1186/1475-2875-9-312
- Tangpukdee N, Duangdee C, Wilairatana P, Krudsood S. Malaria diagnosis: a brief review. Korean J Parasitol. 2009;47: 93–102. doi:10.3347/kjp.2009.47.2.93
- Deutsch-Feldman M, Brazeau NF, Parr JB, Thwai KL, Muwonga J, Kashamuka M, et al. Spatial and epidemiological drivers of Plasmodium falciparum malaria among adults in the Democratic Republic of the Congo. BMJ Glob Health. 2020;5. doi:10.1136/bmjgh-2020-002316
- Hubbard AE, Ahern J, Fleischer NL, Van der Laan M, Lippman SA, Jewell N, et al. To GEE or not to GEE: comparing population average and mixed models for estimating the associations between neighborhood risk factors and health. Epidemiology. 2010;21: 467–474. doi:10.1097/EDE.0b013e3181caeb90
- Wilson JR, Lorenz KA. Generalized estimating equations logistic regression. Modeling Binary Correlated Responses using SAS, SPSS and R. Cham: Springer International Publishing; 2015. pp. 103–130. doi:10.1007/978-3-319-23805-0_6

- Turechek WW, Webster CG, Duan J, Roberts PD, Kousik CS, Adkins S. The use of latent class analysis to estimate the sensitivities and specificities of diagnostic tests for Squash vein yellowing virus in cucurbit species when there is no gold standard. Phytopathology. 2013;103: 1243–1251. doi:10.1094/PHYTO-03-13-0071-R
- Baughman AL, Bisgard KM, Cortese MM, Thompson WW, Sanden GN, Strebel PM. Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis. Clin Vaccine Immunol. 2008;15: 106–114. doi:10.1128/CVI.00223-07
- van Smeden M, Naaktgeboren CA, Reitsma JB, Moons KGM, de Groot JAH. Latent class models in diagnostic studies when there is no reference standard--a systematic review. Am J Epidemiol. 2014;179: 423–431. doi:10.1093/aje/kwt286
- 17. Rogier E, Plucinski M, Lucchi N, Mace K, Chang M, Lemoine JF, et al. Bead-based immunoassay allows sub-picogram detection of histidine-rich protein 2 from Plasmodium falciparum and estimates reliability of malaria rapid diagnostic tests. PLoS One. 2017;12: e0172139. doi:10.1371/journal.pone.0172139
- Deutsch-Feldman M, Aydemir O, Carrel M, Brazeau NF, Bhatt S, Bailey JA, et al. The changing landscape of Plasmodium falciparum drug resistance in the Democratic Republic of Congo. BMC Infect Dis. 2019;19: 872. doi:10.1186/s12879-019-4523-0
- 19. Nychka D, Furrer R, Paige J, Sain S. fields: Tools for spatial data. N/A; 2021.
- 20. Geo-Referenced Infrastructure and Demographic Data for Development 3 (GRID3). GRID3 DRC Health Area Boundaries - Haut-Katanga, Kasaï, Kasaï-Oriental, Kinshasa, and Lomami Provinces, Version 01. In: GRID3 DATA HUB [Internet]. [cited 22 Oct 2022]. Available: https://data.grid3.org/datasets/GRID3::grid3-drc-health-area-boundaries-haut-katanga-kasa%C3%AFkasa%C3%AF-oriental-kinshasa-and-lomami-provinces-version-01/about
- MEASURE Evaluation. Mapping the Stages of MEASURE Evaluation's Data Use Continuum to DHIS 2: An Example from the Democratic Republic of the Congo. Chapel Hill, NC, USA: MEASURE Evaluation; 2019.
- 22. R Core Team. R: A language and environment for statistical' computing. Vienna, Austria: R Foundation for Statistical Computing; 2021.
- 23. Deutsch-Feldman M, Parr JB, Keeler C, Brazeau NF, Goel V, Emch M, et al. The burden of malaria in the democratic republic of the congo. J Infect Dis. 2021;223: 1948–1952. doi:10.1093/infdis/jiaa650
- 24. Beshir KB, Parr JB, Cunningham J, Cheng Q, Rogier E. Screening strategies and laboratory assays to support Plasmodium falciparum histidine-rich protein deletion surveillance: where we are and what is needed. Malar J. 2022;21: 201. doi:10.1186/s12936-022-04226-2



Fig-3_DHS-Prevalence



Fig-1_Study-sites-map

RDT 🗾 Micro 📕 PCR 📰 BBA





Fig-2_study-prev_diganostic-performance

A)